A G Turpie

Summary

Country: Canada

Publications

  1. ncbi A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
    A G Turpie
    McMaster University, Hamilton, Ont, Canada
    N Engl J Med 344:619-25. 2001
  2. ncbi Setting a standard for venous thromboembolism prophylaxis
    A G Turpie
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Am J Health Syst Pharm 58:S18-23. 2001
  3. ncbi Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study
    J D Douketis
    Department of Medicine, McMaster University, Hamilton, Canada
    J Thromb Haemost 3:943-8. 2005
  4. ncbi Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor
    C Kearon
    McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 2:743-9. 2004
  5. ncbi Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice
    A G Turpie
    McMaster University, Hamilton, Ontario, Canada
    Am Heart J 142:S9-15. 2001
  6. ncbi Looking forward in the treatment of deep-vein thrombosis
    A G Turpie
    Department of Medicine, Hamilton Health Sciences Corporation-McMaster Clinic, Hamilton, Ontario, Canada
    Semin Hematol 38:49-57. 2001
  7. ncbi A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy
    W Ageno
    Hamilton Health Sciences Corporation, General Division, McMaster University, Ontario, Canada
    Thromb Haemost 83:849-52. 2000
  8. ncbi Safer anticoagulant therapy after heart valve replacement. Recommendations for less intense regimens
    A G Turpie
    McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
    Postgrad Med 101:85-6, 89-90, 93-4. 1997
  9. ncbi Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B
    A G Turpie
    McMaster University, Hamilton, Ontario
    Can J Cardiol 14:20E-23E. 1998
  10. ncbi Survey of cardiac surgeons' perceptions of the addition of ASA to warfarin for patients with mechanical heart valves
    J G Ray
    Department of Medicine, McMaster University, Hamilton, Ontario
    Can J Cardiol 13:1162-5. 1997

Collaborators

Detail Information

Publications10

  1. ncbi A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
    A G Turpie
    McMaster University, Hamilton, Ont, Canada
    N Engl J Med 344:619-25. 2001
    ..To determine the optimal dose for phase 3 studies, we conducted a dose-ranging study in which Org31540/SR90107A was compared with a low-molecular-weight heparin, enoxaparin, in patients undergoing total hip replacement...
  2. ncbi Setting a standard for venous thromboembolism prophylaxis
    A G Turpie
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Am J Health Syst Pharm 58:S18-23. 2001
    ..Fondaparinux sodium, a novel antithrombotic agent, is effective for the prevention of VTE, with a favorable safety profile, in patients undergoing major orthopedic surgery...
  3. ncbi Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study
    J D Douketis
    Department of Medicine, McMaster University, Hamilton, Canada
    J Thromb Haemost 3:943-8. 2005
    ..Although hormone replacement therapy (HRT) is associated with an increased risk of deep vein thrombosis (DVT), it is not clear if the risk differs in users of combined estrogen-progestin HRT and estrogen-only HRT...
  4. ncbi Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor
    C Kearon
    McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 2:743-9. 2004
    ..Retrospective analyses suggest that 1 month of anticoagulation is adequate for patients whose venous thromboembolic event was provoked by a transient risk factor...
  5. ncbi Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice
    A G Turpie
    McMaster University, Hamilton, Ontario, Canada
    Am Heart J 142:S9-15. 2001
    ..However, efficacy and safety limitations of these agents have prompted a search for alternative antithrombotic drugs...
  6. ncbi Looking forward in the treatment of deep-vein thrombosis
    A G Turpie
    Department of Medicine, Hamilton Health Sciences Corporation-McMaster Clinic, Hamilton, Ontario, Canada
    Semin Hematol 38:49-57. 2001
    ..Evidence is now emerging that may clarify the role of inferior vena cava filters and thrombolysis in VTE management. Future versions of the ACCP guidelines may be expected to reflect new data from ongoing trials...
  7. ncbi A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy
    W Ageno
    Hamilton Health Sciences Corporation, General Division, McMaster University, Ontario, Canada
    Thromb Haemost 83:849-52. 2000
    ..Furthermore, the induction programme provided simple access to the maintenance programme. Although it required careful monitoring, the programme resulted in a significant saving in personnel time...
  8. ncbi Safer anticoagulant therapy after heart valve replacement. Recommendations for less intense regimens
    A G Turpie
    McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
    Postgrad Med 101:85-6, 89-90, 93-4. 1997
    ..Dr Turpie reviews these and lists the current recommendations of the American College of Chest Physicians...
  9. ncbi Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B
    A G Turpie
    McMaster University, Hamilton, Ontario
    Can J Cardiol 14:20E-23E. 1998
    ..0 mg/kg). The results of the published studies indicate that LMWHs are effective in reducing major ischemic outcomes in patients with unstable angina and non-Q wave MI. The results of the TIMI 11B trial will be available in late 1998...
  10. ncbi Survey of cardiac surgeons' perceptions of the addition of ASA to warfarin for patients with mechanical heart valves
    J G Ray
    Department of Medicine, McMaster University, Hamilton, Ontario
    Can J Cardiol 13:1162-5. 1997
    ..Most surgeons avoid ASA out of concern for the increased risk of hemorrhage and a belief that there is no benefit. These perceptions are not supported by recent scientific data, however...